Literature DB >> 1316494

The Bel-1 protein of human foamy virus activates human immunodeficiency virus type 1 gene expression via a novel DNA target site.

A Keller1, E D Garrett, B R Cullen.   

Abstract

The Bel-1 protein of human foamy virus can activate transcription directed by the long terminal repeat (LTR) promoter of human immunodeficiency virus type 1 (HIV-1). The target sequence for Bel-1 is shown to lie within the HIV-1 LTR U3 region but does not coincide with any previously described factor-binding site. Gene expression directed by an HIV-1 LTR lacking functional sites for the inducible cellular transcription factor NF-kappa B was activated over 100-fold by coexpression of Bel-1. These observations suggest that Bel-1 has the potential to significantly enhance the level of HIV-1 gene expression in cells dually infected with HIV-1 and human foamy virus.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1316494      PMCID: PMC241187     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  27 in total

Review 1.  The HIV-1 Tat protein: an RNA sequence-specific processivity factor?

Authors:  B R Cullen
Journal:  Cell       Date:  1990-11-16       Impact factor: 41.582

2.  Mutational analysis of the trans-activation-responsive region of the human immunodeficiency virus type I long terminal repeat.

Authors:  J Hauber; B R Cullen
Journal:  J Virol       Date:  1988-03       Impact factor: 5.103

3.  Simultaneous isolation of simian foamy virus and HTLV-III/LAV from chimpanzee lymphocytes following HTLV-III or LAV inoculation.

Authors:  P L Nara; W G Robey; L O Arthur; M A Gonda; D M Asher; R Yanagihara; C J Gibbs; D C Gajdusek; P J Fischinger
Journal:  Arch Virol       Date:  1987       Impact factor: 2.574

4.  Induction of nuclear NF-kappa B DNA binding activity after exposure of lymphoid cells to soluble tax1 protein.

Authors:  P F Lindholm; S J Marriott; S D Gitlin; C A Bohan; J N Brady
Journal:  New Biol       Date:  1990-11

5.  Activation of the HIV-1 LTR by T cell mitogens and the trans-activator protein of HTLV-I.

Authors:  M Siekevitz; S F Josephs; M Dukovich; N Peffer; F Wong-Staal; W C Greene
Journal:  Science       Date:  1987-12-11       Impact factor: 47.728

6.  Use of eukaryotic expression technology in the functional analysis of cloned genes.

Authors:  B R Cullen
Journal:  Methods Enzymol       Date:  1987       Impact factor: 1.600

7.  Identification of p40x-responsive regulatory sequences within the human T-cell leukemia virus type I long terminal repeat.

Authors:  J Brady; K T Jeang; J Duvall; G Khoury
Journal:  J Virol       Date:  1987-07       Impact factor: 5.103

8.  Requirement of multiple copies of a 21-nucleotide sequence in the U3 regions of human T-cell leukemia virus type I and type II long terminal repeats for trans-acting activation of transcription.

Authors:  K Shimotohno; M Takano; T Teruuchi; M Miwa
Journal:  Proc Natl Acad Sci U S A       Date:  1986-11       Impact factor: 11.205

9.  Characterization of a foamy virus isolated from Cercopithecus aethiops lymphoblastoid cells.

Authors:  D Neumann-Haefelin; A Rethwilm; G Bauer; F Gudat; H zur Hausen
Journal:  Med Microbiol Immunol       Date:  1983       Impact factor: 3.402

10.  cis-acting regulatory regions in the long terminal repeat of simian foamy virus type 1.

Authors:  A Mergia; E Pratt-Lowe; K E Shaw; L W Renshaw-Gegg; P A Luciw
Journal:  J Virol       Date:  1992-01       Impact factor: 5.103

View more
  31 in total

Review 1.  Mechanism of action of regulatory proteins encoded by complex retroviruses.

Authors:  B R Cullen
Journal:  Microbiol Rev       Date:  1992-09

2.  Expanded tissue targets for foamy virus replication with simian immunodeficiency virus-induced immunosuppression.

Authors:  S M Murray; L J Picker; M K Axthelm; M L Linial
Journal:  J Virol       Date:  2006-01       Impact factor: 5.103

3.  Human foamy virus bel1 sequence in patients with autoimmune rheumatic diseases.

Authors:  Kuang-Hui Sun; Hsiao-Yi Lin; Lee-Wen Chen; Hsiao-Yun Tai; Mei-Lin Lin; Chi-Kuang Feng; Jung-Sung Sung; Hsin-Fu Liu; Wu-Tse Liu
Journal:  Clin Rheumatol       Date:  2005-12-20       Impact factor: 2.980

4.  Expression and maturation of human foamy virus Gag precursor polypeptides.

Authors:  M L Giron; S Colas; J Wybier; F Rozain; R Emanoil-Ravier
Journal:  J Virol       Date:  1997-02       Impact factor: 5.103

5.  In vitro infection of primary and retrovirus-infected human leukocytes by human foamy virus.

Authors:  J A Mikovits; P M Hoffman; A Rethwilm; F W Ruscetti
Journal:  J Virol       Date:  1996-05       Impact factor: 5.103

6.  Increase in the basal transcriptional activity of the human foamy virus internal promoter by the homologous long terminal repeat promoter in cis.

Authors:  M Löchelt; M Aboud; R M Flügel
Journal:  Nucleic Acids Res       Date:  1993-09-11       Impact factor: 16.971

Review 7.  Transgenic and knockout mice in the study of neurodegenerative diseases.

Authors:  A Aguzzi; S Brandner; S Marino; J P Steinbach
Journal:  J Mol Med (Berl)       Date:  1996-03       Impact factor: 4.599

Review 8.  Pathogenesis of human immunodeficiency virus infection.

Authors:  J A Levy
Journal:  Microbiol Rev       Date:  1993-03

9.  Functional domains of the simian foamy virus type 1 transcriptional transactivator (Taf).

Authors:  A Mergia; L W Renshaw-Gegg; M W Stout; R Renne; O Herchenröeder
Journal:  J Virol       Date:  1993-08       Impact factor: 5.103

10.  Further characterization of equine foamy virus reveals unusual features among the foamy viruses.

Authors:  Charles-Henri Lecellier; Manuel Neves; Marie-Lou Giron; Joelle Tobaly-Tapiero; Ali Saïb
Journal:  J Virol       Date:  2002-07       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.